Fichas de Oncología Personalizada 2025
Rutinario
- BRCA1 y BRCA2*
Recomendable actualmente
- CHECK2, PALB2, CDK12,
RAD51D, ATM, FANCA* Inestabilidad de microsatélites
(MSI-H, dMMR)**
** mediante IHQ (MLH1, MSH2, MSH6 y PMS2) o mediante estudio genómico (BAT25 y BAT26, D2S123, D5S346 y D17S250).
No recomendable actualmente
- Aberraciones en el receptor de andrógenos
- PDL1
- PTEN
Recomendada actualmente.- se basa en las recomendaciones actuales de EMEA y FDA.
Referencias:
1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440.
2. To SQ, Kwan EM, Fettke HC, et al. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Jun;73(6):818-821. doi: 10.1016/j.eururo.2018.01.007.
3. González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clin Transl Oncol. 2021 May;23(5):969-979. doi: 10.1007/s12094-021-02561-5.
4. Fenton SE, VanderWeeler DJ, Rebbeck TR, Chen DL. Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433138. doi: 10.1200/EDBK_433138.
